Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T54379
(Former ID: TTDNC00429)
|
|||||
| Target Name |
Wnt signaling pathway (Wnt pathway)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Alopecia [ICD-11: ED70] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 5 Clinical Trial Drugs | + | ||||
| 1 | SM04554 | Drug Info | Phase 2/3 | Alopecia | [2] | |
| 2 | SM-04690 | Drug Info | Phase 2 | Osteoarthritis | [3] | |
| 3 | CWP232291 | Drug Info | Phase 1/2 | Acute myeloid leukaemia | [4] | |
| 4 | SM04755 | Drug Info | Phase 1 | Liver cancer | [5] | |
| 5 | SM08502 | Drug Info | Phase 1 | Solid tumour/cancer | [1] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Modulator | [+] 3 Modulator drugs | + | ||||
| 1 | SM04554 | Drug Info | [6] | |||
| 2 | SM-04690 | Drug Info | [7] | |||
| 3 | SM04755 | Drug Info | [8] | |||
| Inhibitor | [+] 2 Inhibitor drugs | + | ||||
| 1 | CWP232291 | Drug Info | [1] | |||
| 2 | SM08502 | Drug Info | [1] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 2 | ClinicalTrials.gov (NCT03742518) A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT02536833) A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects. | |||||
| REF 4 | ClinicalTrials.gov (NCT03055286) Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients. U.S. National Institutes of Health. | |||||
| REF 5 | ClinicalTrials.gov (NCT02191761) Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. U.S. National Institutes of Health. | |||||
| REF 6 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 7 | Clinical pipeline report, company report or official report of Phrma.org Arthritis 2014. | |||||
| REF 8 | A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects with Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.